Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Marinus Pharmaceuticals, Inc. MRNS
$8.75
-$0.48 (-5.51%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
461388779.00000000
-
week52high
9.82
-
week52low
3.47
-
Revenue
25478000
-
P/E TTM
-17
-
Beta
1.16159100
-
EPS
-0.50000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 12:30
Описание компании
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Truist Securities | Buy | Buy | 22 мар 2022 г. |
| SVB Leerink | Outperform | Outperform | 22 мар 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 22 мар 2022 г. |
| SVB Leerink | Outperform | Outperform | 20 дек 2021 г. |
| Truist Securities | Buy | 25 ноя 2020 г. | |
| Baird | Outperform | Outperform | 09 ноя 2022 г. |
| RBC Capital | Outperform | 20 янв 2023 г. | |
| SVB Leerink | Outperform | Outperform | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Braunstein Scott | A | 360000 | 360000 | 26 янв 2023 г. |
| Braunstein Scott | A | 167205 | 80000 | 26 янв 2023 г. |
| Hulihan Joseph | A | 115418 | 115418 | 26 янв 2023 г. |
| Hulihan Joseph | A | 50516 | 25648 | 26 янв 2023 г. |
| Shafer Christina | A | 78188 | 78188 | 26 янв 2023 г. |
| Shafer Christina | A | 43022 | 17375 | 26 янв 2023 г. |
| Pfanstiel Steven | A | 126585 | 126585 | 26 янв 2023 г. |
| Pfanstiel Steven | A | 52128 | 28130 | 26 янв 2023 г. |
| MANNING MARTHA E | A | 74468 | 74468 | 26 янв 2023 г. |
| MANNING MARTHA E | A | 35205 | 16548 | 26 янв 2023 г. |
Новостная лента
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
11 мая 2023 г. в 09:56
Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to loss of $0.52 per share a year ago.
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
Business Wire
03 мая 2023 г. в 07:01
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present and participate during the following conferences in May. JMP Securities 2023 Life Sciences Conference in New York, NY May 15 at 3:30 p.m. E.T. RBC Annual Healthcare Conference in New York, NY May 16 at 10:00 a.m. E.T. Links to the events can be accessed on the Investor.
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 11, 2023
Business Wire
27 апр 2023 г. в 07:01
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the first quarter ended March 31, 2023 on May 11, 2023. The Company will host a conference call at 8:30 a.m. Eastern Time on May 11, 2023. Participants may access the conference call via webcast on the Investors and Media page of Marinus' website at i.
Marinus Pharmaceuticals (MRNS) Stock Jumps 8.4%: Will It Continue to Soar?
Zacks Investment Research
18 апр 2023 г. в 06:08
Marinus Pharmaceuticals (MRNS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Marinus Pharmaceuticals, Inc. (MRNS) Q4 2022 Earnings Call Transcript
Seeking Alpha
07 мар 2023 г. в 22:04
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS ) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Company Participants Sasha Damouni Ellis - Vice President of Corporate Affairs and Investor Relations Scott Braunstein - Chairman and Chief Executive Officer Christy Shafer - Chief Commercial Officer Joe Hulihan - Chief Medical Officer Steve Pfanstiel - Chief Financial Officer and Chief Operating Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Joon Lee - Truist Securities Rudy - SVB Securities Andrew Tsai - Jefferies Charles Duncan - Cantor Fitzgerald Douglas Tsao - H.C. Wainwright Jay Olson - Oppenheimer Brian Skorney - Baird Jason Butler - JMP Securities Operator Greetings everyone and welcome to the Marinus Pharmaceuticals' Fourth Quarter and Full-Year 2022 Financial Results and Business Update Call.